No translate

Văn Đức Hạnh; Phạm Đình Vụ; Trần Việt Dũng; Phan Đình Phong

doi:10.58354/jvc.89.2019.1204

Home

CA LÂM SÀNG Issue: Số 89, 2019 BỆNH MẠCH VÀNH

No translate

Published: September 11, 2026

10.58354/jvc.89.2019.1204

Abstract

No translate

Keywords

No translate

References

1. Harikrishnan P Gupta T, Kolte D, et al. (2015). Trends in management and outcomes of ST-elevation myocardial infarction in patients with end-stage renal disease in the United States. Am J Cardiol., 115(118): 1033-1041.

2. Li Y Saran R, Robinson B, et al. (2016). US Renal Data System 2015 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis., 67(63)(suppl 61):S61-S305.

3. Maclean JR Kasiske BL, Snyder JJ, et al. (2006). Acute myocardial infarction and kidney transplantation.

J Am Soc Nephrol., 17(13):900-907.

4. Silkensen JR (2000). Long-term complications in renal transplantation.J Am Soc Nephrol., 11(13): 582- 588.

5. Gillingham KJ Matas AJ, Humar A, et al. (2008). 2202 kidney transplant recipients with 10 years of graft function: What happens next? Am J Transplant 2008;, 8: 2410.

6. Brennan DC Lentine KL, Schnitzler MA, et al. (2005). Incidence and predictors of myocardial infarction after kidney transplantation. J Am Soc Nephrol;, 16:496–506.

7. ESC Clinical Practice Guidelines Management of Acute Myocardial Infarction in patients presenting with ST-segment elevation (2017).

8. Rocha R Shayan H, Wei L, Gleason T, Zaldonis D, Pellegrini R, Toyoda Y, Shapiro R, Ahmad F, Bermudez C, (2011). Midterm outcomes of off-pump and on-pump coronary artery revascularization in renal transplant recipients. J Card Surg., 26(26):591-595.

10.

9. Yessayan L Haider M, Venkat KK, et al. (2015). Incidence of contrast-induced nephropathy in kidney transplant recipients. Transplant Proc., 47(42):379-383.

11.

10. D. and Malhotra Kaw, D. (2006). Platelet dysfunction and end-stage renal disease. Semin Dialysis 19: 317–322,

12.

11. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute (2006).

13.

12. Charat Thongprayoon Wisit Cheungpasitporn, Donald G. Mitema , et al. (2017). The effect of aspirin on kidney allograft outcomes; a short review to current studies. J Nephropathol. 2017 Jul;, 6(3): 110–117.

14.

13. T. Chang, Montez-Rath, M., Shen, J, et al. (2014). Thienopyridine use after coronary stenting in low income patients enrolled in medicare part D receiving maintenance dialysis. J Am Heart Assoc 3: e001356.

15.

14. Long Shen Chi Zhang, Min Cui, et al. (2017). Ticagrelor-induced life-threatening bleeding via the cyclosporine-mediated drug interaction: A case report. Medicine (Baltimore). 96(37): e8065.

16.

15. Cosio FG Kasiske B, Beto J, et al. (2004). National Kidney Foundation: Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: A report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant4, [ Suppl 7]:13– 53,2004.

17.

16. Miller LW (2002). Cardiovascular toxicities of immunosuppressive agents. Am J Transplant. 2: 807– 818.

18.

17. Fellstrom B Holdaas H, Jardine AG, et al. (2003). Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators: Effect of fluvastatin on cardiac outcomes in renal transplant recipients: A multicentre, randomised, placebo-controlled trial. Lancet, 361 :2024– 2031.

19.

18. Balog D Maltz H, Cheigh J (1999). Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine. Ann Pharmacother, 33 :1176– 1179.

20.

19. Smith L Buchanan C, Corbett J, et al (2006). A retrospective analysis of ezetimibe treatment in renal transplant recipients. Am J Transplant, 6: 770-774.

21.

20. Mark PB Tutone VK, Stewart GA, et al. (2005). Hypertension, antihypertensive agents and outcomes following renal transplantation. Clinical transplantation., 19:181-192.

22.

21. Dohler B. Opelz G (2014). Cardiovascular death in kidney recipients treated with renin-angiotensin system blockers. Transplantation;, 97:310-315.

23.

22. Fergusson D Knoll GA, Chasse M, et al. (2015). Ramipril versus placebo in kidney transplant patients with proteinuria: a multicentre, double-blind, randomised controlled trial. The lancet Diabetes & endocrinology.

24.

23. Vergoulas G (2007). Antihypertensive agents and renal transplantation. Hippokratia., 11(11): 13–12.

25.

24. Remme W Pitt B, Zannad F, et al. (2003). Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med., 348:1309–1321.

26.

25. Wright RS Sakhuja A, Schold JD, et al. (2016). National Impact of Maintenance Dialysis or Renal Transplantation on Outcomes Following ST Elevation Myocardial Infarction. Am J Nephrol., 44(45): 329-338.

27.

26. Kolte D Gupta T, Khera S, et al. (2017). Management and Outcomes of ST-Segment Elevation Myocardial Infarction in US Renal Transplant Recipients. JAMA Cardiol., 2(3):250-258.

28.

27. Foley RN Collins AJ, Chavers B, et al. (2014). US Renal Data System 2013 annual data report. Am J Kidney Dis., 63(61)(suppl):A67.

Tác giả

Văn Đức Hạnh: Viện Tim mạch Việt Nam - Bệnh viện Bạch Mai; Phạm Đình Vụ: Bác sĩ nội trú, Đại học Y Hà Nội; Trần Việt Dũng: Bác sĩ nội trú, Đại học Y Hà Nội; Phan Đình Phong: Viện Tim mạch Việt Nam - Bệnh viện Bạch Mai;